**AGENIX LIMITED**
爱健克斯有限公司
(ASX: AGX)

ABN 58 009 213 754
465 Auburn Road,
Hawthorn East,Vic, 3123
Australia
www.agenix.com

ASX MEDIA RELEASE 22 November 2010

**Non-Renounceable Rights Issue Acceptances and Shortfall**

Agenix Limited (ASX: AGX) (**Agenix**), advises that it has received acceptances and applications in respect of the following shares and free attaching options:

| | Ordinary Shares | Options | $* |
|---|---|---|---|
| Acceptance of Entitlements | 5,126,686 | 1,025,337 | 120,935 |
| Additional Shares subscribed | 14,313,546 | 2,862,709 | 357,838 |
| Total | 19,440,235 | 3,888,046 | 478,773 |

*before costs of the offer

The Directors reserve the right to place the remaining shortfall of 28,559,448 shares and 5,711,954 free attaching options in accordance with the Prospectus.

The Directors consider this an excellent result in light of the difficulties from which the Company has emerged from. They expressed their thanks to shareholders for this show of support.

Holding statements for the new securities will be dispatched by 26 November 2010 in accordance with the timetable in the prospectus.

## About Agenix Limited

Agenix is a publicly listed, Australian based international biotechnology company with a wholly owned subsidiary in China. The company has two core businesses:

- In **Innovative Biopharmaceuticals,** Agenix has 'in principal' rights to clinically develop a pipeline of innovative and proprietary Hepatitis B therapies for commercialisation in China. Through its wholly owned subsidiary, Agenix Biopharmaceutical (Shanghai), established in 2007, the company has established a collaboration with the Institute of Medicinal Biotechnology (**IMB**) of the Chinese Academy of Medical Sciences in Beijing to develop and commercialise AGX-1009, a next-generation, patented prodrug analog of an existing compound for the treatment of chronic HBV in China.

- In **Medical Diagnostics**, the company's lead indicator is a patented monoclonal antibody diagnostic called Thromboview® that, uniquely, detects live blood clots (DVT and PE) in the human body. ThromboView® has successfully completed two FDA Phase II human clinical trials in the United States. The company is positioning Thromboview® as an innovative diagnostic (a 'theranostic') to support the use of Novel Oral Anti-Coagulants and is seeking a development partner in China to commercialise the indicator.

Agenix has been listed on the Australian Securities Exchange (ASX: AGX) since 1987. Agenix is active in China, and seeking to establish commercial partnerships in the rest of the world. For additional information on Agenix Limited, please visit the company's website at http://www.agenix.com

Yours faithfully,

Nick Weston

**Nicholas Weston**
Executive Chairman
Enclosures: Nil

**CONTACT: Company Secretary Jeffrey Luckins**:
+61 3 9822 8686 or email jluckins@agenix.com